Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax Inc. develops and partners vaccine technologies built around Matrix-M adjuvant technology and protein-based nanoparticles. Company news centers on marketed vaccine products, including Nuvaxovid and R21/Matrix-M, licensing and material-transfer agreements with pharmaceutical companies, and research programs for infectious disease and other vaccine applications.
Recurring updates also cover quarterly financial results, revenue from product sales and partner arrangements, R&D prioritization such as its C. difficile vaccine candidate, operating-efficiency initiatives, investor conference participation, and leadership changes within research and development.
Novavax, Inc. (NASDAQ: NVAX) announced that Gregory M. Glenn, M.D., President of Research and Development, will participate in a panel discussion on COVID-19 vaccines at the 2020 BIO Digital conference on June 9 at 11:30 a.m. EDT. The panel will explore the complexities of vaccine development and the importance of collaboration in bringing vaccines to market. Additionally, Novavax is advancing its NVX-CoV2373 vaccine candidate for COVID-19 with Phase 1 results expected in July 2020, alongside positive Phase 3 results for its NanoFlu vaccine targeting influenza.
Novavax, Inc. (NASDAQ: NVAX) announced a $60 million contract with the U.S. Department of Defense (DoD) to manufacture its COVID-19 vaccine candidate, NVX-CoV2373. The funding will support the production of components required to deliver 10 million doses by the end of 2020. This contract aims to enhance Novavax's U.S. production capacity, facilitating support for the COVID-19 pandemic. The vaccine, incorporating proprietary technologies, shows promise in preclinical trials for generating antibodies to combat the virus.
Novavax (NASDAQ: NVAX) announced the enrollment of the first participants in the Phase 1/2 clinical trial for its coronavirus vaccine, NVX-CoV2373. This vaccine utilizes proprietary nanoparticle technology and Matrix-M™ adjuvant to boost immune response. Preliminary results on immunogenicity and safety are anticipated in July 2020, with the Phase 2 trial set to follow if Phase 1 results are promising. The trial is supported by funding from CEPI, highlighting Novavax's commitment to combating COVID-19.
Novavax (NASDAQ: NVAX) has secured up to $384 million in additional funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to support the clinical development of its coronavirus vaccine, NVX-CoV2373. This funding enhances the rapid scale-up of vaccine manufacturing and the production of Matrix-M™ adjuvant, aiming to significantly boost global vaccine supply. Key plans include initiating a Phase 1/2 clinical trial in Australia and potentially manufacturing over one billion vaccine doses in 2021, highlighting a strong commitment to global equitable access.
Novavax (Nasdaq: NVAX) announced that Dr. Gregory Glenn will present updates on NVX-CoV2373, its coronavirus vaccine candidate, during a COVID-19 webinar on May 13, 2020. This informative session is part of the World Vaccine Congress and aims to address ongoing global vaccine development efforts. NVX-CoV2373, engineered from the SARS-CoV-2 sequence, uses recombinant nanoparticle technology to generate effective immune responses. A Phase 1 clinical trial is set to begin in May 2020, with initial results expected by July. CEPI has provided $4 million to support this initiative.